Previous studies have shown that approximately half of MOG-AD patients will experience recurrent demyelinating attacks; affected individuals may not recover from these attacks, indicating the importance of long-term prophylactic therapy in treating MOG-AD (5–7). The gene discussed is MOG; the disease is Alzheimer disease.